Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
6
×
indiana blog main
6
×
indiana top stories
life sciences
migraine
6
×
national blog main
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
clinical trials
detroit blog main
detroit top stories
eli lilly
fda
national
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
teva pharmaceutical
cancer
cancer immunotherapy
gene therapy
lasmiditan
novartis
american academy of neurology
amgen
biogen
What
bio
new
roundup
approval
companies
drug
class
drugs
fda
ipo
life
migraine
science
week
won
america
announced
approved
arena’s
arguments
bails
big
biogen
biogen’s
biopharmaceutical
bounty
brand
bridgebio
capital
car
cig
comeback
commercialized
competitors
continues
convo
convoluted
corner
deals
decades
Language
unset
Current search:
migraine
×
biotech
×
" indiana blog main "
×
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
5 years ago
Bio Roundup: Head and Spine Previews, Biogen Moves, IPO Dreams & More
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: Moderna’s IPO, Arena’s Comeback, E-Cig Survey & More
@xconomy.com
5 years ago
Eli Lilly Migraine Drug Approved, the Third in New Class of Medicines